Stephanie Trexler, PharmD, BCOP

Lu-PSMA-617 is a radiopharmaceutical that is recommended to be handled with appropriate safety measures to minimize radiation exposure.

Earlier this year, the FDA approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto; Novartis), which is referred to in nuclear medicine literature as 

Lu–prostate-specific membrane antigen–617 (

Lu PSMA-617), for the treatment of PSMA-positive metastatic castration resistant prostate cancer (mCRPC).

Lu-PSMA-617 for patients is based on whether they had previously been treated with at least 1 prior androgen receptor pathway inhibitor or with 1 to 2 prior taxane regimens.

PSMA-positive disease is defined as at least 1 PSMA-positive metastatic lesion and no PSMA-negative lesions, determined with the FDA-approved gallium Ga 68 gozetotide injection (Locametz; Novartis), which is a radioactive diagnostic agent for PET imaging of PSMA-positive lesions, or another approved PSMA-11 imaging agent.

 In men with previously treated PSMA-positive mCRPC, the randomized (2:1), multicenter, open-label VISION trial (NCT03511664) evaluated 

Lu PSMA-617 in combination with best standard of care (BSoC) (n = 551) against BSoC alone (n = 280). BSoC included abiraterone, enzalutamide, bisphosphonates, local radiation therapy, denosumab, and/or glucocorticoids. Patients were not permitted to receive cytotoxic chemotherapy, systemic radioisotopes, or immunotherapy in combination with 

Based on the results of the trial, investigators observed 

Lu-PSMA 617 plus BSoC improved median overall survival (OS) and progression free survival (PFS) compared with BSoC alone. Median OS was 15.3 months in the 

Lu-PSMA-617 group compared with 11.3 months in the control group (HR for death, 0.62; 95% CI, 0.52-0.74; 

 < .001). Median PFS was 8.7 months in the 

Lu-PSMA-617 group compared with 3.4 months in the control group (HR for progression or death, 0.40; 99.2% CI, 0.29-0.57; 

Lu-PSMA-617 is a radioligand therapeutic agent, with the radionuclide lutetium-177 linked to a moiety that binds to PSMA, which is a transmembrane protein expressed in prostate cancer. Upon binding to PSMA-expressing cells, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells, which induces DNA damage and can lead tocell death.

Lu-PSMA-617 is dosed at 7.4 GBq (200 mCi) intravenously every 6 weeks for up to 6 treatments, or until disease progression or unacceptable toxicity. Before administration with 

Lu-PSMA-617, patients’ vital signs should be collected 15 minutes prior, as well as 30 and 60 minutes after administration.

Lu-PSMA-617 is a radiopharmaceutical that is recommended to be handled with appropriate safety measures to minimize radiation exposure. 

Lu-PSMA-617 may be administered intravenously (1-10 minutes) using a disposable syringe fitted with a syringe shield (with or without a syringe pump), as an infusion pump using the gravity method (with or without an infusion pump), or as an infusion using the vial (with a peristaltic infusion pump).

Lu-PSMA-617, the most common adverse events (AEs) they noted included fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. During the trial, 

Lu-PSMA-617 was discontinued in 12% of patients due to any treatment-related AEs. In less than 5% of patients, clinically relevant AEs included dry eye, vertigo, and pancytopenia (including bicytopenia).

Lu-PSMA-617 has labeled warnings for risk of radiation exposure, bone marrow suppression, renal toxicity, embryo-fetal toxicity, and infertility. As a targeted radiopharmaceutical, 

Lu-PSMA-617 contributes to a patient’s cumulative radiation exposure. In accordance with institutional good radiation safety practices and Nuclear Regulatory Commission patient-release guid-ance, it is important to minimize radiation exposure to patients, health care personnel, and household contacts.

Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure. Following administration of 

Lu-PSMA-617, patients also must limit close contact (< 3 ft) with household contacts for 2 days or with children and pregnant women for 7 days. Patients must also refrain from sexual activity for 7 days. Patients should sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Lu-PSMA-617 may cause severe and life-threatening myelosuppression. In the manufacturer’s labeling, grade 3 to 4 anemia was experienced among 13% of patients, grade 3 to 4 neutropenia in 5% of patients, grade 3 to 4 thrombocytopenia in 8% of patients, and grade 3 to 4 lymphocytopenia in 47% of patients. Complete blood counts should be obtained before each treatment with 

Lu-PSMA-617. Withhold, dose reduce, or discontinue 

Lu-PSMA-617 based on the grade of myelosuppression experienced.

Lu-PSMA-617 can also cause severe renal toxicity. During the trial, 3% of patients experienced grade 3 to 4 acute kidney injury. Because of this, patients should be counseled to remain well hydrated. Additionally, patients’ serum creatinine and calculate creatinine clearance should be monitored before each treatment with 

Lu-PSMA-617 is absorbed into the testes, the recommended cumulative dose of 44.4 GBq of 

Lu-PSMA-617 results in a radiation absorbed within the range where 

Lu-PSMA-617 may cause temporary or permanent infertility.

Lu-PSMA-617 have not been established. All radiopharmaceuticals, including 

Lu-PSMA-617, have the potential to cause fetal harm. For male patients with female partners of reproductive potential, patients should be advised to use effective contraception during treatment with 

Lu-PSMA-617 and for 14 weeks after the last dose.

is a clinical oncology pharmacist at the Smilow Cancer Hospital and Yale New Haven Health in Connecticut.

1. FDA approves Pluvicto for metastatic castration-resistant pros-tate cancer. FDA. Updated March 23, 2022. Accessed September 15, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer

2. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp; 2022. Accessed September 10, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf

3. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322

Articles

"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.

Stephanie Trexler, PharmD, BCOP

Articles

Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPC